Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma

NCT02519322 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02519322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02519322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2016
Completion date
January 26, 2023
Enrollment
53 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, mucosal melanoma, ocular melanoma, stage iii acral lentiginous melanoma ajcc v7, stage iiib cutaneous melanoma ajcc v7, stage iiib uveal melanoma ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iiic uveal melanoma ajcc v7, stage iv acral lentiginous melanoma ajcc v6 and v7, stage iv cutaneous melanoma ajcc v6 and v7, stage iv uveal melanoma ajcc v7